用调节剂阻断1-磷酸鞘氨醇受体1可减少免疫细胞浸润并缓解小鼠子宫内膜异位症
研究建立手术诱导的子宫内膜异位症小鼠模型,先确定广谱S1P调节剂FTY720的最佳浓度,再比较FTY720与选择性S1P受体1调节剂SEW2871对病灶生长、纤维化、炎症及免疫细胞浸润的影响。结果显示两者均抑制病灶生长和纤维化,SEW2871对炎症因子表达的抑制更强,淋巴细胞减少主要由FTY720引起,两者均显著减少CD45+和F4/80+细胞浸润。
要点
- FTY720与SEW2871均有效抑制小鼠子宫内膜异位病灶生长和纤维化。
- SEW2871对PTGS-2、IL-1β、TNF-α和TGF-β1表达的抑制强于FTY720。
- 淋巴细胞减少主要由FTY720引起,SEW2871影响较小。
核心结论
- 本研究提示S1P受体1未来可作为子宫内膜异位症的潜在新治疗靶点进行研究。
研究设计与样本
- 建立手术诱导的子宫内膜异位症小鼠模型。
- 预实验取病灶评估纤维化和炎症,确定广谱S1P调节剂FTY720的最佳浓度。
- 随后比较FTY720与选择性S1P受体1调节剂SEW2871对病灶生长、纤维化、炎症和免疫细胞浸润的影响。
主要发现
- FTY720和SEW2871均有效抑制子宫内膜异位病灶的生长和纤维化。
- SEW2871对PTGS-2、IL-1β、TNF-α和TGF-β1等炎症相关细胞因子表达的抑制比FTY720更有效。
- 淋巴细胞减少主要由FTY720引起,而SEW2871的影响较小。
- FTY720和SEW2871均显著减少病灶中CD45+细胞浸润(分别为P = 0.002和P = 0.032)。
- FTY720和SEW2871均显著减少病灶中F4/80+细胞浸润(分别为P < 0.001和P = 0.004),其中FTY720对CD4+ T细胞有强调控作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Do sphingosine 1-phosphate (S1P) modulators have therapeutic effects on endometriosis in mice and, if they do, which receptor is responsible for these effects? DESIGN: A surgically induced endometriosis mouse model was established. In the pilot experiment, lesions were harvested to assess fibrosis and inflammation and determine the optimal concentration of a broad-spectrum S1P modulator, FTY720. Subsequently, FTY720 was compared with a selective S1P receptor 1 modulator, SEW2871 to evaluate their effects on endometriotic lesion growth, fibrosis, inflammation and immune cell infiltration. RESULTS: The results demonstrated that both FTY720 and SEW2871, two S1P receptor modulators, effectively inhibited the growth and fibrosis of endometriotic lesions. SEW2871 inhibited inflammation-related cytokine expression, including PTGS-2, IL-1β, TNF-α and TGF-β1, more effectively compared with FTY720. Lymphopaenia was mainly caused by FTY720, whereas SEW2871 had a lesser effect. Both FTY720 and SEW2871 significantly reduced CD45+ cells (P = 0.002 and P = 0.032, respectively) and F4/80+ cells (P < 0.001 and P = 0.004, respectively) infiltration into the lesions, with FTY720 exerting a strong regulatory effect on CD4+ T cells. CONCLUSIONS: This study suggests that S1P receptor 1 could be investigated as a potential novel therapeutic target for endometriosis in the future.
引用
- Zhang F, Peng M, Zheng X, et al. Blocking sphingosine 1-phosphate receptor 1 with modulators reduces immune cells infiltration and alleviates endometriosis in mice. Reprod Biomed Online. 2023. PMID: 37757611. doi:10.1016/j.rbmo.2023.103304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。